Desmopressin vs Dulaglutide
Head-to-head comparison of Desmopressin (1-Deamino-8-D-arginine vasopressin) and Dulaglutide (Recombinant GLP-1 receptor agonist Fc fusion protein) — benefits, dosing, side effects, research data, and where to buy.
Research Score
| Property | Desmopressin | Dulaglutide |
|---|---|---|
| Category | Cognitive Enhancement | Weight Management |
| Full Name | 1-Deamino-8-D-arginine vasopressin | Recombinant GLP-1 receptor agonist Fc fusion protein |
| Molecular Weight | 1069.22 Da | ~63,000 Da |
| Half-Life | 1.5-3 hours | About 5 days |
| Amino Acids | 9 | N/A |
| Typical Dose | 10-40 mcg intranasal | 0.75-4.5 mg weekly |
| Route | Intranasal/Oral | Subcutaneous |
| Purity | ≥98% | ≥98% |
| Studies Count | 35 | 700 |
| Research Status | Clinical | Approved |
Desmopressin Benefits
- ✓memory consolidation
- ✓reduced pressor burden
- ✓recall support
- ✓short-term learning
Dulaglutide Benefits
- ✓modest weight loss
- ✓lower A1c
- ✓weekly dosing convenience
- ✓cardiometabolic benefit
Desmopressin Dosing
intranasal research dosing|10-40 mcg or IU-equivalent studies|single-dose protocols
Dulaglutide Dosing
0.75-4.5 mg SC weekly|Increase based on response and tolerance|Administer on the same day each week
Desmopressin Side Effects
- ⚠hyponatremia
- ⚠headache
- ⚠nasal irritation
Dulaglutide Side Effects
- ⚠nausea
- ⚠diarrhea
- ⚠injection-site reactions
Research Overview
Desmopressin
The literature is mixed, but desmopressin has shown memory-related effects in selected populations and experimental paradigms. Its cognitive effects are usually discussed as a vasopressin-pathway probe rather than a primary nootropic.
Dulaglutide
Dulaglutide has repeatedly shown small-to-moderate reductions in body weight alongside glycemic improvement in large diabetes trials. It is a useful comparator for GLP-1 receptor agonist effects on appetite and weight.
Ready to buy?
Find both peptides from our verified, lab-tested vendors with purity certificates and third-party testing.